Walder David, O'Brien Mary
Royal Marsden Hospital, UK.
Royal Marsden Hospital, UK. Electronic address: mary.o'
Eur J Cancer. 2017 Apr;75:192-194. doi: 10.1016/j.ejca.2017.01.006. Epub 2017 Feb 23.
In surgical series, cancer-free survival at 5 years is often referred to as a cure. In recent years, attempts to improve cure rates in non-small cell lung cancer (NSCLC) have focussed on earlier diagnosis through cost-effective screening programs. Systemic therapies have historically added only a small benefit to overall survival in both the adjuvant and palliative setting. However, in the last two decades, the development of new treatment options has added incremental improvements in NSCLC survival rates. Patients with a targetable sensitising mutation including epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase rearrangements have significantly better prognosis, and many will survive beyond 5 years. Immunotherapy is an effective treatment in selected patients with NSCLC and is set to cause another leap in 5 year survival rates. Although these patients are not free from disease, survival at 5 years may become the more important end-point as NSCLC becomes seen as a chronic oncological disease.
在外科手术系列研究中，5年无癌生存率常被视为治愈。近年来，通过具有成本效益的筛查项目来提高非小细胞肺癌（NSCLC）治愈率的尝试主要集中在早期诊断上。从历史上看，全身治疗在辅助和姑息治疗环境中对总生存期的益处都很小。然而，在过去二十年中，新治疗方案的发展使NSCLC生存率有了逐步提高。具有可靶向的敏感突变（包括表皮生长因子受体基因突变和间变性淋巴瘤激酶重排）的患者预后明显更好，许多患者将存活超过5年。免疫疗法对部分NSCLC患者是一种有效的治疗方法，并将使5年生存率实现又一次飞跃。尽管这些患者并未完全摆脱疾病，但随着NSCLC被视为一种慢性肿瘤疾病，5年生存率可能会成为更重要的终点指标。
